Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
- ProName: Ledipasvir
- CasNo:1256388-51-8
- Molecular Formula: C49H54F2N8O6
- Appearance: Powder
- Application: Pharmaceutical use
- DeliveryTime: communication
- PackAge: Aluminum foil bag packaging
- Port: china main port
- ProductionCapacity: 100 Kilogram/Week
- Purity: >99%
- Storage: Store in dry,dark,ventilated place
- Transportation: Delivery by EMS;DHL;FEDEX;UPS;TNT
No comments:
Post a Comment